Presented here is ovarian tissue oocyte-in vitro maturation (OTO-IVM), an accessible technique within a medical assisted reproduction (MAR) laboratory offering realistic additional fertility preservation options to patients who need ovarian tissue cryopreservation.
Mature oocyte vitrification is the standard of care to preserve fertility in women at risk of infertility. However, ovarian tissue cryopreservation (OTC) is still the only option to preserve fertility in women who need to start gonadotoxic treatment urgently or in prepubertal children. During ovarian cortex preparation for cryopreservation, medullar tissue is removed. Growing antral follicles reside at the border of the cortex-medullar interface of the ovary and are broken during this process, releasing their cumulus-oocyte complex (COC). By thoroughly inspecting the medium and fragmented medullar tissue, these immature cumulus-oocyte complexes can be identified without interfering with the OTC procedure. The ovarian tissue-derived immature oocytes can be successfully matured in vitro, creating an additional source of gametes for fertility preservation. If OTC is performed within or near a medical assisted reproduction laboratory, all necessary in vitro maturation (IVM) and oocyte vitrification tools can be at hand. Furthermore, upon remission and child wish, the patient has multiple options for fertility restoration: ovarian tissue transplantation or embryo transfer after the insemination of vitrified/warmed oocytes. Hence, ovarian tissue oocyte-in vitro maturation (OTO-IVM) can be a valuable adjunct fertility preservation technique.
Fertility preservation (FP) options for women planned for gonadotoxic treatment, sex-reassignment therapy, or women who have a genetic predisposition for premature ovarian failure, depend on the health and age of the patient, available timeframe, type of treatment, patient's preference, and FP procedures available at the fertility center of choice. Vitrification of mature oocytes obtained after ovarian stimulation with gonadotropins and oocyte retrieval in a medical assisted reproduction (MAR) laboratory cycle is considered the preferred option for FP1,2. However, for prepubertal girls, women in whom the urgent start of gonadotoxic treatment or gonadectomy is required, or women with a high risk of permanent amenorrhea due to gonadotoxic treatment, a cycle of ovarian stimulation with gonadotropins is not possible, and ovarian tissue cryopreservation (OTC), which is an accepted and valid technique for FP1,2,3, is the only option. The goal of OTC is to cryopreserve thousands of dormant primordial follicles in the ovarian cortex tissue, which can resume growth after the transplantation of frozen/thawed tissue onto the remaining ovary or in a peritoneal pocket after the careful screening of minimal residual disease in representative tissue fragments.
In order to obtain cortical fragments of 1-2 mm thickness suitable for cryopreservation, the soft medullar tissue needs to be removed. This medullar tissue typically entails growing follicles in various stages of development that escape the stiff ovarian cortex to allow for their growth and expansion4. For many years, several labs have been investigating the potential of these oocytes recovered from follicles residing in the remnant medullar tissue after ovarian cortical fragment preparation using in vitro maturation (IVM)5,6,7, referred to as ovarian tissue oocyte IVM (OTO-IVM). Antral follicles, even those less than 6 mm in diameter, contain immature oocytes surrounded by cumulus cells that can mature, fertilize, and develop into healthy babies using an IVM system8,9. IVM is considered the standard of care for women at risk for ovarian hyperstimulation syndrome (OHSS), such as polycystic ovary syndrome (PCOS) patients. However, in the field of FP, there are limited data available for IVM in cases with a contraindication for ovarian stimulation; IVM of oocytes collected transvaginally is still considered innovative, and OTO-IVM is considered experimental2,10. That said, the reports of the first live births after OTO-IVM11,12,13 highlight the potential of using OTO-IVM as an add-on technique when OTC is required for FP in patients14.
This study provides technical details to adopt OTO-IVM in the MAR laboratory and illustrates the results obtained in a single center.
The present study on OTO-IVM has been approved by the local Ethical Committee of UZ-Brussels (addendum of project 2008/068 and project 2022/303). All patients signed written informed consent. Each patient was individually assessed by a reproductive medicine specialist physician, navigator nurse, and the referring oncologist to compose the optimal FP treatment plan, taking into account the patient's preferences14. In short, patients eligible for OTC are in urgent need of FP and are less than 36 years of age14. To combine OTC with OTO-IVM, chemo- or radiotherapy cannot have been administered in the 6 months preceding OTC.
1. Laboratory environment and personnel
2. Media preparation
NOTE: Five types of media are used for this procedure (detailed below): OTC handling medium, OTC freezing medium, Search medium, LAG medium, and IVM medium. When preparing media, work aseptically in the flow cabinet, as detailed in section 1. Use new, unopened reagents for every procedure and maintain the sterility of all disposables used to ascertain the sterility of the produced media.
3. Ovarian cortex preparation
NOTE: Laparoscopic whole ovary removal was performed as described by Jadoul et al.15.
4. Search for COCs
5. IVM of COCs
6. Handling mature oocytes
Over the past decade, 98 patients undergoing oophorectomy or ovarian biopsy for OTC were also offered OTO-IVM. The results presented here are an update of the clinical program as published before7,13. Immature oocytes obtained during ovarian tissue processing were matured in vitro predominantly for 30 h. However, a more flexible maturation time was allowed for practical reasons or because of low maturation, ranging from 28-42 h. Patients opted predominantly for oocyte vitrification (85/98) or-upon specific request of the patient-embryos were created by inseminating mature oocytes and embryo vitrification (13/98). A total of 1,417 oocytes were collected in 98 patients aged between 1 and 38 years old who were offered OTC with OTO-IVM. The mean oocyte maturation rate was 40% ± 22% (mean ± SD). The mean maturation rate was lower in prepubertal girls compared to postpubertal women (26% vs. 42%, respectively; Table 1). For 94/98 patients, immature oocytes were found, and at least one metaphase II (MII) was obtained for 86/94 patients after OTO-IVM, indicating that OTO-IVM provided an additional benefit of mature oocytes for cryopreservation in 88% of the OTC population.
Overall, an average of 6.0 ± 6 mature oocytes was obtained in the OTC population (intention to treat, ITT). However, some patients were very young (<5 years old; n = 4) or had a limited amount of ovarian tissue available for OTO-IVM (ovarian biopsy [n = 4] or tumor involvement in the ovary [n = 4]). If only patients with successful OTO-IVM were considered (at least one MII; n = 86), an average of 6.5 ± 6 MII was obtained.
In order to preserve the fertility chances of women, oocyte vitrification was advised for the patients. However, for 13 patients, the couple insisted on creating embryos for FP. Fertilization success was assessed by the presence of two pronuclei (2PN) at approximately 18 h after ICSI. OTO-IVM oocytes showed a 63% fertilization rate (40 2PN/64 MII); 68% of the zygotes developed into cleavage stage embryos of sufficient quality for cryopreservation (27 good quality embryos [GQE]/40 2PN), generating on average 2.1 ± 2 embryos per patient being vitrified. In brief, GQEs sufficient for cryopreservation are defined as six cells or more and a maximum of 20% fragmentation7.
Data on the warming of OTO-IVM oocytes or embryos are scarce. Of 86 patients with cryopreserved gametes/embryos, 17 patients returned to the MAR clinic with a desire for pregnancy. Ten decided to use their cryopreserved material obtained after OTO-IVM; seven patients showed sufficient ovarian activity to start an in vitro fertilization (IVF)/ICSI stimulation cycle with fresh oocytes. Five patients had OTO-IVM oocytes warmed, with a survival rate of 75% (58/77). These oocytes showed a similar potential for fertilization (48%; 28/58) compared to fresh OTO-IVM oocytes, but a lower embryo development rate, generating only 29% (8/28) GQEs for transfer or cryopreservation, an average of 1.3 ± 1 per patient. Out of eight created embryos, seven were warmed, of which six embryos did not lead to pregnancy, and one embryo led to a healthy live birth.
For five patients, OTO-IVM embryos were warmed. A total of nine embryos were warmed, of which one did not survive, two were genetically tested for breast cancer (BRCA) genes and considered unsuitable for transfer, four did not lead to a pregnancy, and two embryos led to two healthy babies born in two patients.
Overall, three of the 10 patients who returned to the MAR clinic with a desire for pregnancy had a healthy baby with their cryopreserved OTO-IVM material (30%), without the need for additional laparoscopic surgery for tissue transplantation and the risk of reintroducing malignancy.
Figure 1: Ovary incision and isolation of ovarian cortex and COCs. (A) Longitudinal incision of the ovary through the cauterization lesion to cut the ovary in half. (B) Removal of the inner medullar tissue to isolate the cortical ovarian tissue with scissors. (C) Medullar fragments and follicular fluids remaining after ovarian cortex isolation. (D) Filtration of the medium through a 70 µm mesh filter to isolate COCs and remove contaminating red blood cells. (E) Representative image of a COC before IVM; scale bar corresponds to 100 µm. Please click here to view a larger version of this figure.
ITT | Total | Prepubertal | Adult |
n | 98 | 11 | 87 |
average # Cortex fragments/patient | 18.5 ± 10 | 11.5 ± 7 | 19.4 ± 10 |
average # COC/patient | 14.5 ± 12 | 16.2 ± 16 | 14.2 ± 12 |
average # MII/patient | 6.0 ± 6 | 4.3 ± 5 | 6.2 ± 6 |
total # COC | 1417 | 178 | 1239 |
total # MII | 563 | 47 | 516 |
MII rate | 40% | 26% | 42% |
Table 1: The outcome of OTO-IVM in the total population and stratified according to menarche. Abbreviations: ITT = intention to treat; n = amount of subjects; COC = cumulus oocyte complex; MII = metaphase II oocyte.
The priority of the FP procedure is always to manipulate and freeze the ovarian cortex according to the standard operating protocol that has been validated in the clinic. A drawback in FP is the absence of a standard protocol available in the published literature regarding OTC and OTO-IVM. It is difficult to assess the efficiency and validity of the techniques and adaptations since there is a large time gap between freezing/vitrification and thawing/warming in a clinical setting. If changes to the OTC protocol are made to augment the efficiency of OTO-IVM, it is vital to validate the adapted OTC protocol for tissue health upon cryopreservation and thawing. In this report, the protocol for OTC, routinely used at Brussels IVF at the University Hospital of VUB, Brussels, prescribes that the medulla is pared down from the ovarian cortex using scissors. As such, medullar tissue is systematically cut into small fragments, and COCs are set free. Other labs prepare the ovarian cortex using scalpels, where the bulk of the medullar tissue is scooped from the cortex shell. Here, additional cutting of the large medullar piece is needed to release the COC. Puncturing visible, large antral follicles with a needle upon receiving the ovary in the laboratory is contraindicated, as these punctures damage the ovarian cortex. Secondly, the yield of COC aspiration from large antral follicles in an ovary ex vivo is low.
If ovarian tissue is transported from a local hospital to a center of expertise for tissue cryopreservation, this transport is performed under cold conditions (0-4 °C) for up to 24 h with minimal tissue damage16. During transport, the ovary is suspended in saline solution, phosphate-buffered saline, or more complex media like Leibowitz's L15, alpha modification of Eagle's medium, or Custodiol; however, data about tissue viability (and OTO-IVM success) related to different transport media are scarce16. The OTC protocol states that the ovarian cortex should be processed at 0-4 °C to slow metabolism and reduce ischemic damage. However, chilling oocytes influences their cytoskeletal conformation17 and membrane integrity18, and impairs the maturation potential of ovarian tissue-derived oocytes19 (immediate processing at 37 °C results in 42% MII, whereas transport for 2-5 h on ice reduces the MII rate to 27%19). Other centers perform ovarian tissue processing at room temperature or 37 °C, but the presented results reflect tissue processing in cold conditions with intermittent transport of medullar fragments and medium to a 37 °C heated stage for COC search.
For IVM the standard protocol, used for infertility patients with a PCOS background, was used9. A commercial IVM medium is used to culture immature oocytes, where the manufacturer recommends supplementing the IVM medium with maternal serum. In order to avoid bias of unknown substances delivered by maternal serum, the currently presented IVM results are obtained using commercial HSA as the protein source in the IVM medium. Novel biphasic IVM culture systems have been developed, which augment the yield in mature oocytes in an infertile PCOS population20 as well as in OTO-IVM21. The continued efforts in optimizing IVM protocols will likely enhance, also the efficiency of OTO-IVM in fertility preservation patients. Immature oocytes are incubated at 20% O2 during the maturation phase, unlike incubation under 6% O2 for embryonic preimplantation development. IVM in reduced oxygen conditions impairs blastocyst development22, hence it is critical to perform the 30 h incubation period in IVM medium in 20% O2. Maturation is assessed after 30 h by the enzymatic and mechanical removal of surrounding cumulus cells. Sometimes, an additional overnight culture in IVM medium of cumulus-free oocytes was applied to increase the yield of mature oocytes; However, only a limited amount of additional mature oocytes were obtained after this prolonged maturation time. Mature oocytes were cryopreserved using the standard protocol for oocyte vitrification at Brussels IVF23.
As shown in the results, OTO-IVM can be offered to most patients undergoing OTC; however, for patients under 5 years of age, the likelihood of obtaining oocytes is low7 due to the limited differentiation between cortex and medulla tissue and the absence of antral follicles. In general, maturation rates of OTO-IVM are lower for children as compared to adults, most likely due to the intrinsic differences between adult and prepubertal folliculogenesis and hence the compromised developmental capacity due to, for example, increased aneuploidy24,25. Similarly, advanced age (>30 years) has been described to affect the OTO-IVM maturation rate25. Further, when ovaries have cysts or malignant involvement, the yield after OTO-IVM can be low26, as is also seen when an ovarian biopsy is taken instead of a whole ovary. The selection of patients for OTO-IVM is important in determining successful outcomes.
A subset of FP patients have a contraindication for ovarian tissue transplantation (high risk of reintroducing malignant cells in, for example, ovarian cancers) or host-hostility in autoimmune diseases, and need to wait until human in vitro folliculogenesis is clinically applicable to have their genetically-own child. OTO-IVM is the only clinically applicable FP option for these patients.
Although the clinical relevance of OTO-IVM is evident, some issues need to be solved to validate this technique before the experimental label of the technique can be lifted. The impact of the temperature of transport and processing requires investigation in more detail. The standard IVM protocol used for infertile patients may not be efficacious for immature oocytes harvested from ovarian tissue, and IVM culture media and methods require finetuning to enhance oocyte quality after maturation. The lower oocyte quality of OTO-IVM oocytes is illustrated by a lower survival rate after vitrification/warming of OTO-IVM oocytes (75%), as compared to mature oocytes harvested after ovarian stimulation in an oocyte donation program (93.7%)23. More data on oocyte vitrification efficiency and the developmental capacity of OTO-IVM oocytes are necessary to estimate the true potential of OTO-IVM in FP. The population of patients who are suitable for oophorectomy/ovarian biopsy for FP is shrinking, as a result of the advances in therapeutical agents rendering cancer therapies more efficient and less gonadotoxic.
In conclusion, performing OTO-IVM creates an additional option for FP and offers a realistic additional chance of achieving pregnancy, as shown by the three healthy children born in three individual patients in this small cohort of 10 patients who warmed their cryopreserved OTO-IVM oocytes or embryos. Therefore, OTO-IVM is considered a valuable add-on tool that can be used when cryopreservation of ovarian tissue is the best approach for preserving a patient's fertility.
The authors have nothing to disclose.
This work was conducted at the IVF laboratory of Brussels IVF, Universitair Ziekenhuis of VUB, Brussels. The authors would like to thank all Brussels IVF laboratory team members for their high skills, accuracy, and flexibility needed to establish a fertility preservation unit within a MAR laboratory.
1000 µL filter tips | Eppendorf/VWR International | 613-6780 | COC search |
Benchtop Cooler | Fisher Scientific | 15-350-54 | Benchtop Cooler lid is used to prepare the tissue, Benchtop Cooler tube holder to keep cryovials with freezing medium cooled |
Corning Cell culture dish, non-treated, 100 mm | Corning/VWR International | 430591 | Dish for ovarian tissue preparation |
CryoSure-DMSO | WAK Chemicals | 0482 | Cryoprotectant for ovarian tissue cryopreservation |
Cumulase | Origio/CooperSurgical | 16125000A | recombinant human hyaluronidase enzyme for cumulus cell removal after IVM |
Decontamination spray: Suprox | Medipure LTD | MP016 | Desinfectant solution for aseptic handling with bactericide and sporicide action |
Disposable scalpels | Swann-Morton | 0511 | Ovarian tissue preparation |
Falcon 14 mL Round Bottom Polystyrene Test Tube, with Snap Cap, Sterile | Falcon/VWR International | BDAA352057 | Medium container |
Falcon Cell strainer 70 µm | Falcon/VWR International | 352350 | Filter for elimination of red blood cell contamination and COC search |
Freeze control Ampoule Cryochamber and Temperature Controller | Cryologic | CL-8800i CC60AS | Slow freezing machine |
FSH: Menopur 75 IU | Ferring | BE197504 | Follicle Stimulating Hormone : Supplement for IVM medium |
Handling pipette 290-310 µm | Vitrolife | 15538 | COC search: gentle transfer of COC without damaging oocyte-cumulus cell connectivity |
hCG: Brevactid 5000 IE | Ferring | 5008001036 | Human Chorionic Gonadotropin : Supplement for IVM medium |
High security tube | CryoBioSystem | 022252 | cryovial, heat-sealed for safe cryostorage |
HSA-solution | Vitrolife | 10064 | Human serum Albumin: supplement for IVM medium |
Leibovitz's L-15 medium | Life Technologies Europe | 31415-029 | Handling medium for ovarian tissue preparation |
MediCult IVM system | Origio/CooperSurgical | 82214010 | medium for IVM containing both LAG and IVM medium. IVM medium needs to be supplemented as detailed in the protocol |
METZENBAUM fino scissors 140 mm | Chirurgical Maintenance | VIZ08280314 | Medium size scissors for initial medulla removal |
Nunc 4-well dishes for IVF | Nunc/VWR International | 144444 | COC collection during COC search and IVM culture |
Nunc Invitro fertilization Petri Dish with Vented Lid, 60 mm, Non-Pyrogenic, Sterile | Thermo Scientific/VWR | NUNC150270 | Dish for COC search |
Oocyte handling medium : Flushing Medium with heparin | Origio/CooperSurgical | 10765060 | Search medium for COC search |
Ovoil | Vitrolife | 10029 | oil for IVM culture |
Penicillin/Streptomicin mix | Life Technologies Europe | 15140-148 | Supplement for OTC handling medium |
Scissors, curved, 150 mm long, 20 mm blade | Chirurgical Maintenance | VIREBST999-SC | Small size scissors for residual medulla removal |
.